OBJECTIVE: To systematically develop a quality indicator (QI) set for systemic lupus erythematosus (SLE). METHODS: We used a validated process that combined available scientific evidence and expert consensus to develop a QI set for SLE. We extracted 20 candidate indicators from a systematic literature review of clinical practice guidelines pertaining to SLE. An advisory panel revised and augmented these candidate indicators and, through 2 rounds of voting, arrived at 25 QIs. These QIs advanced to the next phase of the project, in which we employed a modification of the RAND/UCLA Appropriateness Method. A systematic review of the literature was performed for each QI, linking the proposed process of care to potential improved health outcomes. After reviewing this scientific evidence, a second interdisciplinary expert panel convened to discuss the evidence and provide final ratings on the validity and feasibility of each QI. RESULTS: The final expert panel rated 20 QIs as both valid and feasible. Areas covered included diagnosis, general preventive strategies (e.g., vaccinations, sun avoidance counseling, and screening for cardiovascular disease), osteoporosis prevention and treatment, drug toxicity monitoring, renal disease, and reproductive health. CONCLUSION: We employed a rigorous multistep approach with systematic literature reviews and 2 expert panels to develop QIs for SLE. This new set of indicators provides an opportunity to assess health care quality in patients with SLE and represents an initial step toward the important goal of improving care in this patient population.
OBJECTIVE: To systematically develop a quality indicator (QI) set for systemic lupus erythematosus (SLE). METHODS: We used a validated process that combined available scientific evidence and expert consensus to develop a QI set for SLE. We extracted 20 candidate indicators from a systematic literature review of clinical practice guidelines pertaining to SLE. An advisory panel revised and augmented these candidate indicators and, through 2 rounds of voting, arrived at 25 QIs. These QIs advanced to the next phase of the project, in which we employed a modification of the RAND/UCLA Appropriateness Method. A systematic review of the literature was performed for each QI, linking the proposed process of care to potential improved health outcomes. After reviewing this scientific evidence, a second interdisciplinary expert panel convened to discuss the evidence and provide final ratings on the validity and feasibility of each QI. RESULTS: The final expert panel rated 20 QIs as both valid and feasible. Areas covered included diagnosis, general preventive strategies (e.g., vaccinations, sun avoidance counseling, and screening for cardiovascular disease), osteoporosis prevention and treatment, drug toxicity monitoring, renal disease, and reproductive health. CONCLUSION: We employed a rigorous multistep approach with systematic literature reviews and 2 expert panels to develop QIs for SLE. This new set of indicators provides an opportunity to assess health care quality in patients with SLE and represents an initial step toward the important goal of improving care in this patient population.
Authors: Michael F Marmor; Ronald E Carr; Michael Easterbrook; Ayad A Farjo; William F Mieler Journal: Ophthalmology Date: 2002-07 Impact factor: 12.079
Authors: Rita Mangione-Smith; Alison H DeCristofaro; Claude M Setodji; Joan Keesey; David J Klein; John L Adams; Mark A Schuster; Elizabeth A McGlynn Journal: N Engl J Med Date: 2007-10-11 Impact factor: 91.245
Authors: Chris Tonner; Laura Trupin; Jinoos Yazdany; Lindsey Criswell; Patricia Katz; Edward Yelin Journal: Arthritis Care Res (Hoboken) Date: 2010-06 Impact factor: 4.794
Authors: Tzu-Chieh Lin; Michael F Marmor; Medha Barbhaiya; Hongshu Guan; Sarah K Chen; Candace H Feldman; Karen H Costenbader Journal: Arthritis Care Res (Hoboken) Date: 2018-11 Impact factor: 4.794
Authors: Claire E H Barber; Deborah A Marshall; Nanette Alvarez; G B John Mancini; Diane Lacaille; Stephanie Keeling; J Antonio Aviña-Zubieta; Dmitry Khodyakov; Cheryl Barnabe; Peter Faris; Alexa Smith; Raheem Noormohamed; Glen Hazlewood; Liam O Martin; John M Esdaile Journal: J Rheumatol Date: 2015-07-15 Impact factor: 4.666
Authors: Jinoos Yazdany; Candace H Feldman; Jun Liu; Michael M Ward; Michael A Fischer; Karen H Costenbader Journal: Arthritis Care Res (Hoboken) Date: 2014-04 Impact factor: 4.794
Authors: Christie M Bartels; Heather Johnson; Katya Voelker; Carolyn Thorpe; Patrick McBride; Elizabeth A Jacobs; Nancy Pandhi; Maureen Smith Journal: Arthritis Care Res (Hoboken) Date: 2014-09 Impact factor: 4.794
Authors: L Carli; C Tani; F Querci; A Della Rossa; S Vagnani; C Baldini; R Talarico; A d'Ascanio; R Neri; A G Tavoni; S Bombardieri; M Mosca Journal: Clin Rheumatol Date: 2013-03-03 Impact factor: 2.980
Authors: Matthew L Basiaga; Evanette K Burrows; Michelle R Denburg; Kevin E Meyers; Andrew B Grossman; Petar Mamula; Robert W Grundmeier; Jon M Burnham Journal: J Pediatr Date: 2016-09-09 Impact factor: 4.406